Adrian NEWMAN-TANCREDI

Dr. Adrian NEWMAN-TANCREDI

Neurolixis, Castres, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MMM. J. Millan
M. J. Millan
AGA. Gobert
A. Gobert
FLF. Lejeune
F. Lejeune
ADA. Dekeyne
A. Dekeyne
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
DCD. Cussac
D. Cussac
Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine (5-HT)2C receptors, respectively. It also interacted with h5-HT2B receptors (6.6), whereas it showed low affinity at native (rat)/cloned, human 5-HT2A (<5.0/5.3) and 5-HT1A (<5.0/5.2) receptors, and negligible (<5.0) affinity for other 5-HT receptors. In antibody capture/scintillation proximity assays, agomelatine concentration dependently and competitively abolished h5-HT2C receptor-mediated activation of Gq/11 and Gi3 (pA2 values of 6.0 and 6.1). As measured by [3H]phosphatidylinositol depletion, agomelatine abolished activation of phospholipase C by h5-HT2C (pKB value of 6.1) and h5-HT2B (pKB value of 6.6) receptors. In vivo, it dose dependently blocked induction of penile erections by the 5-HT2C agonists (S)-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine (Ro60,0175) and 1-methyl-2-(5,8,8-trimethyl-8H-3-aza-cyclopenta[a]inden-3-yl) ethylamine (Ro60,0332). Furthermore, agomelatine dose dependently enhanced dialysis levels of dopamine in frontal cortex of freely moving rats, whereas they were unaffected in nucleus accumbens and striatum. Although the electrical activity of ventrotegmental dopaminergic neurons was unaffected agomelatine, it abolished their inhibition by Ro60,0175. Extracellular levels of noradrenaline in frontal cortex were also dose dependently enhanced by agomelatine in parallel with an acceleration in the firing rate of adrenergic cell bodies in the locus coeruleus. These increases in noradrenaline and dopamine levels were unaffected by the selective melatonin antagonist N-[2-(5-ethyl-benzo[b]thien-3-yl)ethyl] acetamide (S22153) and likely flect blockade of 5-HT2C receptors inhibitory to frontocortical dopaminergic and adrenergic pathways. Correspondingly, distinction to agomelatine, melatonin showed negligible activity 5-HT2C receptors and failed to modify the activity of adrenergic and dopaminergic pathways. In conclusion, in contrast to melatonin, agomelatine behaves as an antagonist at 5-HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.

1 January 2002 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MMMark J. Millan
Mark J. Millan
LMLisa Maiofiss
Lisa Maiofiss
DCDidier Cussac
Didier Cussac
VAValérie Audinot
Valérie Audinot
Jean Albert BoutinJean Albert Boutin
Jean Albert Boutin
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents were determined at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease: human (h)D1, hD2S, hD2L, hD3, hD4, and hD5 receptors; human 5-hydroxytryptamine (5-HT)1A, h5-HT1B, h5-HT1D, h5-HT2A, h5-HT2B, and h5-HT2Creceptors; hα1A-, hα1B-, hα1D-, hα2A-, hα2B-, hα2C-, rat α2D-, hβ1-, and hβ2-adrenoceptors (ARs); and native histamine1 receptors. A correlation matrix (294 pKi values) demonstrated substantial “covariance”. Correspondingly, principal components analysis revealed that axis 1, which accounted for 76% variance, was associated with the majority of receptor types: drugs displaying overall high versus modest affinities migrated at opposite extremities. Axis 2 (7% of variance) differentiated drugs with high affinity for hD4 and H1 receptors versus hα1-AR subtypes. Five percent of variance was attributable to axis 3, which distinguished drugs with marked affinity for hβ1- and hβ2-ARs versus hD5and 5-HT2A receptors. Hierarchical (cluster) analysis of global homology generated a dendrogram differentiating two major groups possessing low versus high affinity, respectively, for multiple serotonergic and hD5 receptors. Within the first group, quinpirole, quinerolane, ropinirole, and pramipexole interacted principally with hD2, hD3, and hD4receptors, whereas piribedil and talipexole recognized dopaminergic receptors and hα2-ARs. Within the second group, lisuride and terguride manifested high affinities for all sites, with roxindole/bromocriptine, cabergoline/pergolide, and 6,7-dihydroxy-N,N-dimethyl-2-ammotetralin (TL99)/apomorphine comprising three additional subclusters of closely related ligands. In conclusion, an innovative multivariate analysis revealed marked heterogeneity in binding profiles of antiparkinson agents. Actions at sites other than hD2 receptors likely participate in their (contrasting) functional profiles.

27 April 2000 in Synapse
Verified
Journal Article
Closed access
PDF file
AGAlain Gobert
Alain Gobert
JRJean-Michel Rivet
Jean-Michel Rivet
FLFrançoise Lejeune
Françoise Lejeune
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
AAAgnes Adhumeau-Auclair
Agnes Adhumeau-Auclair
MMMark J. Millan
Mark J. Millan

12 December 2013 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
AGAlvaro L. Garcia-Garcia
Alvaro L. Garcia-Garcia
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
ELE. David Leonardo
E. David Leonardo

1 July 2013 in Neuropharmacology
Verified
Journal Article
Open access
AAA.L. Auclair
A.L. Auclair
JMJ.C. Martel
J.C. Martel
MAM.B. Assié
M.B. Assié
LBL. Bardin
L. Bardin
PHP. Heusler
P. Heusler
RDR. Depoortère
R. Depoortère
Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) milnacipran and is currently under development for the treatment of major depressive disorder. LVM was benchmarked against two other SNRIs, duloxetine and venlafaxine, in biochemical, neurochemical and pharmacological assays. LVM exhibited high affinity for human NE (Ki = 92.2 nM) and 5-HT (11.2 nM) transporters, and potently inhibited NE (IC50 = 10.5 nM) and 5-HT (19.0 nM) reuptake (human transporter) in vitro. LVM had 2-fold greater potency for norepinephrine relative to serotonin reuptake inhibition (i.e. NE/5-HT potency ratio: 0.6) and 17 and 27 times higher selectivity for NE reuptake inhibition compared with venlafaxine and duloxetine, respectively. LVM did not exhibit affinity for 23 off-target receptors. LVM (i.p.) increased cortical extracellular levels of 5-HT, and NE (minimal effective doses: MEDs = 20 and 10 mg/kg, respectively). In anti-depressive/anti-stress models, i.p. LVM diminished immobility time in the mouse forced swim (MED = 20 mg/kg) and tail suspension (MED = 2.5 mg/kg) tests, and reduced shock-induced ultrasonic vocalizations in rats (MED = 5 mg/kg). Duloxetine and venlafaxine were less potent (MEDs ≥ 10 mg/kg). At doses active in these three therapeutically-relevant models, LVM (i.p.) did not significantly affect spontaneous locomotor activity. In summary, LVM is a potent, selective inhibitor of NE and 5-HT transporters with preferential activity at the former. It is efficacious in models of anti-depressive/anti-stress activity, with minimal potential for locomotor side effects.

1 August 1998 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
SGSamantha Gavaudan
Samantha Gavaudan
CCCaroline Conte
Caroline Conte
CCChristine Chaput
Christine Chaput
MTManuelle Touzard
Manuelle Touzard
MMMark J Millan
Mark J Millan